Trial · NCT03348631
Adverse events326
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 326
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 7 | 16 | |
| other | Anemia | Blood and lymphatic system disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 16 | 42 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 1 | 16 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 0 | 42 | |
| other | Lymph node pain | Blood and lymphatic system disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 0 | 16 | |
| other | Lymph node pain | Blood and lymphatic system disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 | |
| other | Cardiac arrest | Cardiac disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 0 | 16 | |
| other | Cardiac arrest | Cardiac disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 | |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 1 | 16 | |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 0 | 42 | |
| other | Sinus tachycardia | Cardiac disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 0 | 16 | |
| other | Sinus tachycardia | Cardiac disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 | |
| other | Ear and labyrinth disorders - Other, specify | Ear and labyrinth disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 1 | 16 | |
| other | Ear and labyrinth disorders - Other, specify | Ear and labyrinth disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 0 | 42 | |
| other | Tinnitus | Ear and labyrinth disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 1 | 16 | |
| other | Tinnitus | Ear and labyrinth disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 | |
| other | Hypothyroidism | Endocrine disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 0 | 16 | |
| other | Hypothyroidism | Endocrine disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 | |
| other | Blurred vision | Eye disorders | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 1 | 16 | |
| other | Blurred vision | Eye disorders | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 1 | 42 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03348631/events